Business conflict and global politics: The pharmaceutical industry and the global protection of intellectual property rights

Review of International Political Economy

Volumn 20, Issue 1, 2013, Pages 121-152

  Roemer Mahler, Anne ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

business; Global governance; intellectual property; pharmaceutical industry

Indexed keywords

EID: 84873122492     PISSN: 09692290     EISSN: 14664526     Source Type: Journal    
DOI: 10.1080/09692290.2011.645848     Document Type: Article

References (123)

1. ACT UP. 2002. "Accelerating "Access" Serves Pharmaceutical Companies While Corrupting Health Organizations". Paris Press statement 15 May. Available at: http://www.actupny.org/reports/Durban-accessPR.html (last accessed 27 February 2012)
2. Adamini, S., Maarse, H., Versluis, E. and Light, D. W. 2009. Policy Making on Data Exclusivity in the European Union: From Industrial Interests to Legal Realities. Journal of Health Politics, Policy and Law, 34: 979-1010. doi:10.1215/03616878-2009-033
3. Alexander, J. 2008. "SPIC Urges Govt to Safeguard Export Business of SME Units While Reframing Counterfeit Definition". PharmBiz. New Delhi. Available at: http://saffron.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47069§ionid=19 (last accessed: 27 February 2012).
4. Anderson, T. 2009. Confusion over Counterfeit Drugs in Uganda. The Lancet, 373: 2097-8. doi:10.1016/S0140-6736(09)61134-X
5. Angell, M. 2005. The Truth About the Drug Companies, Melbourne: Scribe.
6. Baron, D. P. 1995. Integrated Strategy: Market and Nonmarket Components. California Management Review, 37: 73-85. doi:10.2307/41165788
7. Baron, D. P. 1999. Integrated Market and Nonmarket Strategies in Client and Interest Group Politics. Business & Politics, 1: 7-34.
8. Baron, D. P. 2006. Business and Its Environment, Upper Saddle River, NJ: Prentice Hall.
9. Baumgartner, F. R. and Leech, B. L. 1998. Basic Interests: The Importance of Groups in Politics and Political Science, Princeton, NJ: Princeton University Press.
10. Bayart, T. O. and Elliot, K. A. 1994. Reciprocity and Retaliation in US Trade Policy, Washington, DC: Institute for International Economics.
11. Chatterjee, P. 2010. India Combats Confusion over Counterfeit Drugs. The Lancet, 375(9714): 542 doi:10.1016/S0140-6736(10)60214-0
12. Chaudhuri, S. 2005. The WTO and India's Pharmaceutical Industry. Patent Protection, TRIPS and Developing Countries, New Delhi: Oxford University Press.
13. Clapp, J. 2005. "The Privatization of Global Environmental Governance: ISO 14000 and the Developing World". In The Business of Global Environmental Governance, Edited by: Levy, D. L. and Newell, D. 223-47. Cambridge, MA: MIT Press.
14. Clift, C. 2007. "Data Protection and Data Exclusivity in Pharmaceuticals and Agrochemicals". In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices, Edited by: Krattiger, Anton, Mahoney, R. T. and Nelson, L. 436431Oxford: MIHR.
15. Cockburn, I. M. 2007. "Is the Pharmaceutical Industry in a Productivity Crisis?". In Innovation Policy and the Economy, Edited by: Jaffe, A. B., Lerner, J. and Stern, S. Vol. 7, 1-32. Cambridge, MA: MIT.
16. Coen, D. and Grant, W. 2005. "Business and Government in International Policy-making: The Transatlantic Business Dialogue as an Emerging Business Style?". In The Politics of International Trade in the Twenty-First Century: Actors, Issues and Regional Dynamics, Edited by: Kelly, D. and Grant, W. 47-70. London: Palgrave.
17. Correa, C. 1993. TRIPS: An Asymetric Negotiation. Third World Economics, 72: 9-11.
18. Correa, C. 2006. "Protecting Test Data for Pharmaceutical and Agrochemical Products under Free Trade Agreements". In Negotiating Health: Intellectual Property and Access to Essential Medicines, Edited by: Roffe, P., Vivas-Eugui, D. and Tansey, G. 85-114. London: Earthscan.
19. Cox, R. W. 1994. Power and Profits: US Policy in Central America, Lexington, KY: University Press of Kentucky.
20. CPTech, Oxfam and TAC. 2001. "Email sent to IP-Health: Comment on the Attaran/Gillespie-White and Phrma Surveys of Patents on Antiretroviral Drugs in Africa". 16 October. (On file with the author)
21. Cutler, C., Haufler, V. and Porter, T. 1999. Private Authority and International Affairs, Albany, NY: SUNY.
22. Dahl, R. 1961. Who Governs? Democracy and Power in an American City, New Haven, CT: Yale University Press.
23. De Vre, R., Goeller, S. and Pawlu, C. 2008. Pharma's Generics Opportunity in Central and Eastern Europe. McKinsey Quarterly, Available at: http://mkqpreview2.qdweb.net/Pharmas_generics_opportunity_in_Central_and_Eastern_Europe_2186 (last accessed 27 February 2012).
24. DiMasi, J. A., Hansen, R. W. and Grabowski, H. G. 2003. The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics, 22: 151-85. doi:10.1016/S0167-6296(02)00126-1
25. Drahos, P. 1995. Global Property Rights in Information: The Story of TRIPS at the GATT. Prometheus, 13: 6-19. doi:10.1080/08109029508629187
26. Drahos, P. 2002. "Developing Countries and International Intellectual Property Standard-Setting". In Integrating Intellectual Property Rights and Development Policy. Report of the Commission on Intellectual Property Rights London Study Paper 8 Available at: http://www.iprcommission.org/graphic/documents/study_papers.htm (Last accessed: 27 February 2012).
27. Drahos, P. 2003a. "Expanding Intellectual Property's Empire: The Role of FTAs". Barcelona: GRAIN. Available at: http://www.grain.org/article/entries/3614-expanding-intellectual-property-s-empire-the-role-of-ftas. (Last accessed: 27 February 2012).
28. Drahos, P. 2003b. When the Weak Bargain with the Strong: Negotiations in the World Trade Organization. International Negotiation, 8: 79-109. doi:10.1163/138234003769590677
29. Epstein, E. 1969. The Corporation in American Politics, Englewood Cliffs, NJ: Prentice-Hall.
30. European Union. 2003. "Council Regulation (EC) No. 1383/2003 of 22 July 2003 concerning customs action against goods suspected of infringing certain intellectual property rights and the measures to be taken against goods found to have infringed such rights, Official Journal of the European Union, L 196, Brussels: 7-14".
31. European Union. 2004. "Directive 2004/48/EC of the European Parliament and of the Council of 29 April 2004 on the Enforcement of Intellectual Property Rights". Official Journal of the European Union, L157, Brussels: 45-86
32. European Union. 2005. "Strategy for the Enforcement of Intellectual Property Rights in Third Countries, Official Journal of the European Union, C129, Brussels: 3-16".
33. European Union. 2006. EU-US Action Strategy for the Enforcement of Intellectual Property Rights, Vienna: European Commission.
34. Falkner, R. 2008. Business Power and Conflict in International Environmental Politics, Basingstoke: Palgrave Macmillan.
35. Ferguson, T. 1984. From Normalcy to New Deal: Industrial Structure, Party Competition, and American Public Policy in the Great Depression. International Organization, 38: 41-93. doi:10.1017/S0020818300004276
36. Finger, M. 2005. "The New Water Paradigm: The Privatization of Governance and the Instrumentalization of the State". In The Business of Global Environmental Governance, Edited by: Levy, D. L. and Newell, D. 275-304. Cambridge, MA: MIT Press.
37. Fligstein, N. 1996. Markets as Politics: A Political-Cultural Approach to Market Institutions. American Sociological Review, 61: 656-73. doi:10.2307/2096398
38. Foster, G. K. 1998/1999. Opposing Forces in a Revolution in International Patent Protection: The US And India in the Uruguay Round and Its Aftermath. UCLA Journal of International Law and Foreign Affairs, 283: 283-323.
39. G8 Summit. 2007. "Summit Declaration: Growth and Responsibility in the World Economy". Heiligendamm. Available at: http://www.g-8.de/Content/EN/Artikel/__g8-summit/anlagen/2007-06-07-gipfeldokument-wirtschaft-eng,templateId=raw,property=publicationFile.pdf/2007-06-07-gipfeldokument-wirtschaft-eng.pdf (Last accessed 27 February 2012)
40. Gale, J. and Buchholz, R. A. 1987. "The Political Pursuit of Competitive Advantage: What Business Can Gain from Government". In Business Strategy and Public Policy: Perspectives from Business and Academia, Edited by: Marcus, A. A., Kaufman, A. M. and Beam, D. R. 31-41. New York, NY: Quorum.
41. Getz, K. A. 1997. Research in Corporate Political Action: Integration and Assessment. Business & Society, 36: 32-77. doi:10.1177/000765039703600103
42. Gibbs, D. N. 1991. The Political Economy of Third World Intervention: Mines, Money and US Policy in the Congo Crisis, Chicago, IL: University of Chicago Press.
43. Gill, S. and Law, D. 1989. Global Hegemony and the Structural Power of Capital. International Studies Quarterly, 33: 475-99. doi:10.2307/2600523
44. Government of India. 1970. "The Patents Act, 1970 (39 of 1970)". New Delhi
45. Granovetter, M. 1985. Economic Action, Social Structure, and Embeddedness. American Journal of Sociology, 91: 481-510. doi:10.1086/228311
46. Granovetter, M. and Swedborg, R. 1992. The Sociology of Economic Life, Oxford: Westview.
47. Gray, N. 2006. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive, May: 77-101.
48. Greenwood, J. and Jacek, H. 2000. Organized Business and the New Global Order, Basingstoke: Macmillan.
49. Greidner, W. 1997. One World Ready or Not: The Manic Logic of Global Capitalism, New York, NJ: Simon&Schuster.
50. Guennif, S. 2004. "AIDS in India: Public Health Related Aspects of Industrial and Intellectual Property Rights Policies in a Developing Country". In CSH Occasional Paper No. 8, Paris: Centre d'Economie de Paris Nord, Universite Paris 13.
51. Hall, R. B. and Biersteker, T. J. 2002. The Emergence of Private Authority in Global Governance, Cambridge: Cambridge University Press.
52. Haufler, V. 2001. A Public Role for the Private Sector, Washington, DC: Carnegie Endowment for International Peace.
53. Helfer, L. H. 2004. Regime Shifting: The TRIPS Agreement and New Dynamics of International Intellectual Property Lawmaking, Princeton, NJ: Princeton University Program in Law and Public Affairs. Research Paper No. 04-004.
54. Hillman, A. J., Keim, G. D. and Schuler, D. 2004. Corporate Political Activity: A Review and Research Agenda. Journal of Management, 30: 837-57.
55. IMS. 2008a. "IMS Health Reports Annual Global Generics Prescription Sales Growth of 3.6 Per cent, to $78 Billion". Press release. Washington, DC 10 December Available at: http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=2943d52288d1e110VgnVCM100000ed152ca2RCRD&vgnextfmt=default (Last accessed: 27 February 2012).
56. IMS. 2008b. "IMS Health Reports Global Prescription Sales Grew 6.4 Per cent in 2007, to $712 Billion". Press release. Washington, DC 12 April Available at: http://imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=d24d88cef5305210VgnVCM100000ed152ca2RCRD&vgnextchannel=41a67900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default (Last accessed 27 February 2012).
57. IMS. 2010. "IMS Health Forecasts Global Pharmaceutical Market Growth of 5-7 Per cent in 2011, Reaching $880 Billion". Press release. Norwalk, CT Available at: http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=119717f27128b210VgnVCM100000ed152ca2RCRD (Last accessed 27 February 2012).
58. IMS. 2011. "IMS Institute Forecasts Global Spending on Medicines to Reach Nearly $1.1 Trillion by 2015". Press release. Norwalk, CT Available at: http://www.imshealth.com/portal/site/ims/menuitem.d248e29c86589c9c30e81c033208c22a/?vgnextoid=01146b46f9aff210VgnVCM100000ed152ca2RCRD (Last accessed 27 February 2012).
59. International Chamber of Commerce. 2011. "Business Action to Stop Counterfeiting and Piracy". Available at: http://www.iccwbo.org/bascap/id1127/index.html (Last accessed 27 February 2012).
60. Jack, A. 2009a. GSK to Slash Drug Prices for Developing Countries. Financial Times, Available at: http://www.ft.com/cms/s/0/4a3bb8be-dd4f-11de-ad60-00144feabdc0.html#axzz1nbaKYHlR (Last accessed 27 February 2012).
61. Jack, A. 2009b. Turning the World of Drugs Upside Down. Financial Times, Available at: http://www.ft.com/cms/s/0/0670e678-dd03-11de-ad60-00144feabdc0.html#axzz1nbaKYHlR (Last accessed 27 February 2012).
62. Jack, A. 2010. AstraZeneca Ties up with Indian Drugmaker. Financial Times, Available at: http://www.ft.com/cms/s/0/c4499166-2d0f-11df-8025-00144feabdc0.html#axzz1nbaKYHlR (Last accessed 27 February 2012).
63. Kongolo, T. 2001. Public Interest Versus the Pharmaceutical Industry's Monopoly in South Africa. Journal of World Intellectual Property, 4: 609-27. doi:10.1111/j.1747-1796.2001.tb00130.x
64. Krikorian, G. P. and Szymkowiak, D. M. 2007. Intellectual Property Rights in the Making: The Evolution of Intellectual Property Provisions in US Free Trade Agreements and Access to Medicines. The Journal of World Intellectual Property, 10: 388-418. doi:10.1111/j.1747-1796.2007.00328.x
65. Kumar, N. 2002. "Intellectual Property Rights, Technology and Economic Development: Experiences of Asian Countries". Study Paper 1b, prepared for the UK Commission on Intellectual Property Rights, London
66. Lanoszka, A. 2003. The Global Politics of Intellectual Property Rights and Pharmaceutical Drug Policies in Developing Countries. International Political Science Review, 24: 181-96. doi:10.1177/0192512103024002002
67. Law, J. 2006. Big Pharma: How the World's Biggest Drug Companies Control Illness, London: Constable.
68. Le Deu, F., Parekh, R. N. and Suessmuth-Dyckerhoff, C. 2008. Seizing China's Pharma Opportunity. McKinsey Quarterly, (February). Available at: http://www.mckinseyquarterly.com/Seizing_Chinas_pharma_opportunity_2102 (Last accessed 27 February 2012).
69. Levy, D. L. and Kolk, A. 2002. Strategic Responses to Global Climate Change: Conflicting Pressures on Multinationals in the Oil Industry. Business & Politics, 4: 275-300. doi:10.2202/1469-3569.1042
70. Lindblom, C. E. 1977. Politics and Markets: The World's Political-Economic Systems, New York, NY: Basic Books.
71. Liu, P. 1994. US Industry's Influence on Intellectual Property Negotiations and Special 301 Action. UCLA Pacific Basin Law Journal, 13: 87-117.
72. Mara, K. 2010a. Debate Erupts over WHO Police Work against 'Counterfeit' Drugs Trade. IP-Watch, 20 May. Available at: http://www.ip-watch.org/2010/05/20/debate-erupts-over-who-police-work-against-counterfeit-drugs-trade (Last accessed 27 February 2012).
73. Mara, K. 2010b. Pointed Exchange of Views at WHO Briefing on Counterfeit Drugs. IP-Watch, 31 March. Available at: http://www.ip-watch.org/2010/03/31/flare-up-in-who-briefing-on-counterfeit (Last accessed: 27 February 2012).
74. Matthews, D. 2007. The Role of International NGOS in the Intellectual Property Policy-Making and Norm-Setting Activities of Multilateral Institutions. Chicago-Kent Law Review, 82(2): 1369-86.
75. Matthews, D. 2011. Intellectual Property, Human Rights and Development, the Role of NGOS and Social Movements, Cheltenham: Edward Elgar.
76. Mattli, W. and Buethe, T. 2003. Setting International Standards. Technological Rationality or Primacy of Power?. World Politics, 56: 1-42. doi:10.1353/wp.2004.0006
77. McNeil, D. G. Jr. 2001. Indian Company Offers to Supply AIDS Drugs at Low Cost in Africa. New York Times, Available at: http://www.nytimes.com/2001/02/07/world/indian-company-offers-to-supply-aids-drugs-at-low-cost-in-africa.html?pagewanted=all&src=pm (Last accessed 27 February 2012).
78. Milner, H. 1988. Resisting Protectionism: Global Industries and the Politics of International Trade, Princeton, NJ: Princeton University Press.
79. MSF. 2002. "Equitable Access: Scaling up HIV/AIDS Treatment in Developing Countries". 15 November Available at: http://www.msf.or.jp/files/20021129-1.pdf (Last accessed 27 February 2012).
80. New, W. and Mara, K. 2010. Emerging Economies' New Initiative on Falsified and Substandard Medicines. IP-Watch, 22 October. Available at: http://www.ip-watch.org/2010/10/22/emerging-economies-new-initiative-on-falsified-and-substandard-medicines (Last accessed 27 February 2012).
81. Nowell, G. 1994. Mercantile States and the World Oil Cartel, 1900-1939, Ithaca, NY: Cornell University Press.
82. Offe, C. and Ronge, V. 1982. "Theses on the Theory of the State". In Classes, Power and Conflict, Edited by: Giddens, A. and Held, D. 249-56. Basingstoke: Macmillan.
83. Ohmae, K. 1995. The End of the Nation State: The Rise of Regional Economies, New York, NY: Free Press.
84. Ostry, S. 1990. Governments and Corporations in a Shrinking World: Trade and Innovation Policies in the United States, Europe and Japan, New York, NY: Council on Foreign Relations.
85. Oxfam. 2002. "Generic Competition, Price and Access to Medicines: The Case of Antiretrovirals in Uganda". Washington, DC: Oxfam Briefing Paper No. 26.
86. Oxfam. 2011. "Eye on the Ball: Medicine Regulation, Not IP Enforcement, Can Best Deliver Quality Medicines". Oxfam Briefing Paper. Oxford Available at: http://www.oxfam.org.uk/resources/policy/health/downloads/bp143-eye-on-the-ball-medicine-regulation-020211-en.pdf (Last accessed 27 February 2012).
87. Pear, R. 2003. Drug Companies Increase Spending on Efforts to Lobby Congress and Governments. New York Times, Available at: http://www.nytimes.com/2003/06/01/us/drug-companies-increase-spending-on-efforts-to-lobby-congress-and-governments.html?pagewanted=all&src=pm (Last accessed 27 February 2012).
88. Pécoul, B., Chirac, P., Trouiller, P. and Pinel, J. 1999. Access to Essential Drugs in Poor Countries: A Lost Battle?. Journal of the American Medical Association, 281: 361-7. doi:10.1001/jama.281.4.361
89. PhRMA. 1999. "Submission of the Pharmaceutical Reseach and Manufacturers of America for the 'Special 301'". India: Report on Intellectual Property Barriers. Available at: www.phrma.org/issues/nte/html (Accessed 2 February 2009).
90. PhRMA. 2003. "Patent Incentives for Discovery of New Medicines Must Be Maintained, Phrma Tell Lawmakers". Press release. Washington, DC 17 June. Available at: www.phrma.org/mediaroom/press/releases/17.06.2003.747.cfm
91. Powell, W. W. and DiMaggio, P. J. 1991. The New Institutionalism in Organizational Analysis, Chicago, IL: University of Chicago Press.
92. Przeworski, A. and Wallerstein, M. 1988. Structural Dependence of the State on Capital. American Political Science Review, 82: 11-29. doi:10.2307/1958056
93. Redwood, H. 1994. New Horizons in India: The Consequences of Pharmaceutical Patent Protection, Suffolk: Oldwicks Press.
94. Roemer-Mahler, A. 2010. "Business Conflict and Global Politics: The Pharmaceutical Industry and the Global Governance of Pharmaceutical Intellectual Property". Unpublished PhD thesis, Oxford: Department of International Development, University of Oxford.
95. Roland Berger Strategy Consultants. 2010. "Fight or Flight? Diversification Vs. Rx-Focus in Big Pharma's Quest for Sustained Growth". Munich, Roland Berger
96. Ryan, M. P. 1998. The Function-Specific and Linkage-Bargain Diplomacy of International Intellectual Property Lawmaking. University of Pennsylvania Journal of International Economic Law, 19: 535-86.
97. Saez, C. 2011. WHO Members to Work to Disentangle Problem of Fake Medicines, IP Issues. IP-Watch, 26 February. Available at: http://www.ip-watch.org/2011/02/26/who-members-to-work-to-disentangle-problem-of-fake-medicines-ip-issues (Last accessed 27 February 2012).
98. Santoro, M. A. 1995. Pfizer: Global Protection of Intellectual Property. Harvard Business School Case Study 9-392-073, Cambridge, MA: Harvard Business School Publishing.
99. Schacht, W. H. and Thomas, J. R. 2007. "Patent Law and Its Application to the Pharmaceutical Industry. An Examination of the Drug Price Competition and Patent Term Restoration Act of 1984 ("the Hatch-Waxman Act")". In Patent Technology, Edited by: Branes, J. M. 39-76New York, NY: Nova. Transfer and Industrial Competition
100. Schuler, D. A., Rehbein, K. and Cramer, R. 2002. Pursuing Strategic Advantage through Political Means: A Multivariate Approach. Academy of Management Journal, 45: 659-72. doi:10.2307/3069303
101. Sell, S. 2003. Private Power, Public Law: The Globalization of Intellectual Property Rights, Cambridge: Cambridge University Press.
102. Sell, S. 2007. TRIPS Plus Free Trade Agreements and Access to Medicines. Liverpool Law Review, 28: 41-75. doi:10.1007/s10991-007-9011-8
103. Sell, S. and Prakash, A. 2004. Using Ideas Strategically: The Contest between Business and N.G.O. Networks in Intellectual Property Rights. International Studies Quarterly, 48: 143-75. doi:10.1111/j.0020-8833.2004.00295.x
104. Shadlen, K. C. 2007. The Political Economy of AIDS Treatment: Intellectual Property and the Transformation of Generic Supply. International Studies Quarterly, 51(3): 559-81. doi:10.1111/j.1468-2478.2007.00464.x
105. Shaffer, B. 1995. Firm-Level Responses to Government Regulation: Theoretical and Research Approaches. Journal of Management, 21: 495-514. doi:10.1177/014920639502100305
106. Shankar, R. 2008. "WHO's New Definition of Counterfeit Drugs Intended to Hurt Indian Cos: IPA". Pharmabiz. 19 November. Mumbai. Available at: http://saffron.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47036§ionid=5 (Last accessed 27 February 2012).
107. Skidmore, D. 1995. Review: The Business of International Politics. Mershon International Studies Review, 39: 246-54. doi:10.2307/222753
108. Stopford, J. and Strange, S. 1991. Rival States, Rival Firms: Competition for World Market Shares, Cambridge: Cambridge University Press.
109. Strange, S. 1996. The Retreat of the State: The Diffusion of Power in the World Economy, Cambridge: Cambridge University Press.
110. t'Hoen, E. 2003. TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, Doha and Beyond. Chicago Journal of International Law, 3: 27-48.
111. t'Hoen, E. 2009. The Global Politics of Pharmaceutical Monopoly Power. Drug Patents, Access, Innovation and the Application of the WTO Doha Declaration on TRIPS and Public Health, Diemen: AMB.
112. US Chamber of Commerce. 2007. "US Chamber and Coalition against Counterfeiting and Piracy Launch 'Campaign to Protect America". Washington, DC 14 June
113. Watal, J. 2001. Intellectual Property Rights in the WTO and Developing Countries, New Delhi: Oxford University Press.
114. Weissman, R. 1996. A Long, Strange TRIPS: The Pharmaceutical Industry's Drive to Harmonize Global Intelletual Property Rules, and the Remaining WTO Legal Alternatives Available to Third World Countries. University of Pennsylvania Journal of International Economic Law, 17: 1069-125.
115. White, G. 1993. The Political Analysis of Markets. IDS Bulletin, 24(3): 1-11. doi:10.1111/j.1759-5436.1993.mp24003001.x
116. WHO. 1999. "Counterfeit Drugs: Guidelines for the Development of Measures to Combat Counterfeit Drugs". Geneva WHO. Available at: http://whqlibdoc.who.int/hq/1999/WHO_EDM_QSM_99.1.pdf (Last accessed 27 February 2012).
117. WHO. 2011a. "Impact Technology Working Group". See: http://www.who.int/impact/working_groups/wg_technology/en/index.html (Last accessed 27 February 2012).
118. WHO. 2011b. "WHOs Relationship with the International Medical Products Anti-Counterfeiting Taskforce". Doc. No. A/SSFFC/WG/4 (23 September), Geneva Working Group of Member States on Substandard/Spurious/Falsely-Labelled/Falsified/Counterfeit Medical Products. Available at: http://apps.who.int/gb/ssffc/pdf_files/A_SSFFC_WG2_4-en.pdf (Last accessed 27 February 2012).
119. WHO, UNAIDS and UNICEF. 2010. Towards Universal Access: Scaling up Priority H.I.V./A.I.D.S. Interventions in the Health Sector. Progress Report 2010, Geneva: WHO.
120. WIPO. 1988. "Existence, Scope and Form of Generally Internationally Accepted and Applied Standards/Norms for the Protection of Intellectual Property',". document number: WO/INF/29 September 1988; issued as GATT document number MTN.GNG/NG11/W/24/Rev.1. Geneva: GATT.
121. World Bank. 2010. "Indicators: GDP Growth (Annual%)". Washington, DC: World Bank. Available at: http://data.worldbank.org/indicator (Last accessed 27 February 2012).
122. WTO. 2001. "Doha Declaration on the TRIPS Agreement and Public Health". WTO Doc. No.: WT/MIN(01)/DEC/2, Geneva: WTO
123. Zimmerman, R. and Pesta, J. 2001. Drug Industry, AIDS Community is Jolted by Cipla AIDS Drug Offer. Wall Street Journal, Available at: http://survivreausida.net/a4686-drug-industry-aids-community-is-jolted-by-c.html (Last accessed 27 February 2012).